|
BQC19
|
The population is composed of patients (including pregnant women and pediatric patients) who have been hospitalized with moderate to severe illness and who underwent a PCR test for SARS-CoV-2 with a negative result.
-
Newborns
-
-
Twins
-
-
Countries
-
-
Ethnic Origin
-
-
Health Status
-
- Participants are included if they were hospitalized with a moderate or severe illness and who underwent a PCR test for SARS-CoV-2 with a negative result.
-
Other Criteria
-
Inclusion criteria for adults and children:
* Patients who were tested for COVID-19 at one of the participating institutions of the BQC19.
Inclusion criteria for adults only:
* Adults capable of consent to research.
* Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator.
* Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator.
-
Supplementary Information about selection criteria
-
Recruitement of adult patients ended on February 14th 2023.
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited during a hospital stay in a COVID unit or in intensive care.
Recruitement of adult patients ended on February 14th 2023.
-
Number of Participants
-
911
-
Number of Participants with Biological Samples
-
911
-
Supplementary Information about selection criteria
-
BQC19 - Inpatient controls
|
Demographic information, patient type and profile (COVID status, severe/mild disease, age, sex, weight, height, smoking status, drug use, healthcare worker status, etc.), medical history, results of any routine laboratory tests ordered by the attending physician, COVID-19 symptoms information are collected through questionnaires. Obstetrics information (postpartum, pregnancy outcome, baby's COVID status, other infectious pathogens of the mother), is collected from a subset of participants.
Pediatric information (birth weight and length of gestation), is collected from a subset of participants.
Vital sign information such as body temperature, blood pressure, breathing rate and heart rate, oxygen saturation on room air and oxygen therapy are collected.
Blood and stool samples are collected.
-
Start Date
-
2020-05
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Data sources - Biosamples
-
-
Files
-
BCQ19 - Inpatient controls - Enrollment
|
|
BQC19
|
The population is composed of adult participants (including pregnant women) with mild illness or who are asymptomatic and who underwent a PCR test for SARS-CoV-2 with a negative result.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Ethnic Origin
-
-
Health Status
-
- Participants with asymptomatic and mild symptoms who underwent a PCR test for SARS-CoV-2 with a negative result are included.
-
Other Criteria
-
Inclusion:
* Patients who were tested for COVID-19 at one of the participating institutions of the BQC19.
* Adults capable of consent to research.
* Adults rendered incapable of consent to research due to COVID-19 (sudden and temporary incapacity), if represented by an agent, guardian or curator.
* Adults incapable of consent to research due to a condition other than COVID-19, if represented by an agent, guardian or curator.
Due to a decrease in PCR screenings, the study stopped requesting for mandatory PCR test since November 2022.
-
Supplementary Information about selection criteria
-
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited in outpatient clinics or post-COVID clinics.
Recruitement ended on February 14th 2023.
-
Number of Participants
-
136
-
Number of Participants with Biological Samples
-
136
-
Supplementary Information about selection criteria
-
BQC19 - Outpatient controls
|
Patient type and profile information such as COVID status, severe or mild illness, age, sex, weight, height, smoking status, drug use, including whether the individual is a health care worker, obstetrical component such as post-partum state, pregnancy outcome, COVID status of the baby, presence of other infectious pathogens from the mother, medical history and COVID-19 symptoms information are collected through questionnaire.
Pediatric component such as weight at birth and duration of gestation are collected from a subset of participants.
Level of fitness and frailty are also assessed through the Clinical frailty score test.
-
Start Date
-
2020-03
-
End Date
-
2023-02
-
Data sources
-
-
Files
-
BCQ19 - Outpatient controls - Enrollment
|
|
CHMS
|
The population is composed of Canadian individuals between 3 and 79 years of age living in privately occupied dwellings in one of the ten provinces. For the pilot phase and Cycle 1, the minimum age of participants included was 6 years old.
-
Minimum age
-
3
-
Maximum age
-
79
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
-
Ethnic Origin
-
-
Health Status
-
-
Other Criteria
-
Exclusion: People living in Indian Reserves or Crown lands, residents of institutions, full-time members of the Canadian Forces and residents of certain remote regions.
-
Supplementary Information about selection criteria
-
-
Sources of recruitment
-
-
General Population
-
-
Supplementary Information
-
The CHMS will collect data in 16 sites across the country. The collection sites are located in seven provinces: Prince Edward Island, New Brunswick, Quebec, Ontario, Saskatchewan, Alberta and British Columbia, not including the territories, Native reserves or military.
-
Number of Participants
-
5,797
-
Number of Participants with Biological Samples
-
5,651
-
Supplementary Information about selection criteria
-
Cycle 1: 5604 participants
Cycle 2: 6395 participants
Cycle 3: 5785 participants
Cycle 4: 5794 participants
Cycle 5: 5786 participants
Cycle 6: 5797 participants
CHMS population
|
The pre-test consisted of a home interview followed by a series of direct physical and laboratory measures conducted in a clinic in the South Calgary Health Centre.
-
Start Date
-
2004-10
-
End Date
-
2004-12
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Data sources - Biosamples
-
-
Files
-
CHMS - Pilot Phase
|
|
CLOUD
|
The population is composed of adolescents who are able to participate in Vancouver (British Columbia), Edmonton (Alberta), Toronto (Ontario), or Sherbrooke (Quebec).
-
Minimum age
-
12
-
Maximum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Vancouver, Edmonton, Toronto, Sherbrooke
-
Ethnic Origin
-
-
Health Status
-
-
Other Criteria
-
Non-smoking and non-ENDS using participants will be recruited to match the age and sex distribution of the
ENDS and cigarette smoking groups.
-
Sources of recruitment
-
-
General Population
-
-
Supplementary Information
-
Participants are recruited through social media, educational initiatives in schools, awareness programs, the study website, and online health research platforms like REACH BC.
-
Number of Participants
-
100
-
Number of Participants with Biological Samples
-
100
-
Supplementary Information about selection criteria
-
**This population includes**
* 50 ENDS users
* 50 non-e-cigarette users
CLOUD - Adolescents
|
Demographic, exposure, and medical history, along with vaping habits (device type, frequency, e-liquid composition, and flavorings), are recorded. Vaping dependence is assessed using the modified Fagerström test. Validated respiratory symptom questionnaires include the American Thoracic Society Questionnaire (ATSQ), A modified SGRQ and Visual Analog Scale is completed.
Pulmonary function tests is conducted, along with oscillometry using the tremoFlo™ C-100 system.
Multiple Breath Washout (MBW) is completed (some sites only).
Cardiopulmonary Exercise Testing (CPET) is performed to assess cardiac, metabolic, and ventilatory parameters. A pulmonary MRI is completed, with qualitative image analysis for lung abnormalities.
Blood and lung biospecimens are collected. An induced sputum collection will be performed on adolescent participants for lung biospecimens.
-
Start Date
-
2025-05
-
End Date
-
2027-05
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Other : Magnetic Resonance Imaging (MRI)
-
Data sources - Biosamples
-
-
Blood
-
Other : Induced sputum
-
Files
-
CLOUD - Adolescents - Visit 1
|
|
DOORWAY
|
Children aged 1 to 17 years visiting one of five pediatric emergency departments namely CHU Ste-Justine, Montreal Children's Hospital, CHU de Laval, Children's Hospital of Eastern Ontario, Children’s Hospital of London Health Sciences Centre with a moderate or severe asthma exacerbation (PRAM score ≥4).
-
Minimum age
-
1
-
Maximum age
-
17
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Montreal, Quebec, Ottawa and London
-
Ethnic Origin
-
-
Health Status
-
- Moderate to severe asthma exacerbation
-
Other Criteria
-
Participants were eligible if they: (1) were aged 1–17 years; (2) had asthma, defined as: (i) prior diagnosis of asthma made by a physician; (ii) prior documented episode of acute cough, wheezing and/or dyspnoea with significant response to inhaled β2-agonists or to oral corticosteroids; (iii) in a child aged <2 years, three or more episodes of cough, wheezing and/or dyspnoea, including the index visit or (iv) previous lung function tests showing significant reversibility postbronchodilation (≥12% FEV1 or ≥25% Rrs at 4–8 Hz) or a positive provocation test (PC20 ≤8 mg/mL or provocation dose (to increase Rrs by 50% or more (PD50) ≤8 mg/mL), in keeping with the American Thoracic Society and European Respiratory Society criteria; (3) presented with an acute episode of cough, wheezing and/or dyspnoea; (4) had moderate-to-severe airway obstruction, defined as a PRAM score >3 at baseline; (5) had a good understanding of English or French and (6) were accompanied by parents or legal guardians.
Patients were excluded if they presented: (1) with another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic fibrosis); (2) with a reasonable suspicion of bronchiolitis or foreign body aspiration; (3) a history of hypersensitivity to salbutamol, ipratropium bromide or oral prednisolone; (4) a relative or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine in a susceptible child or (5) with confirmed or suspected pregnancy status.
-
Sources of recruitment
-
-
Specific Population
-
-
Participants from Existing Studies
-
-
Number of Participants
-
975
-
Number of Participants with Biological Samples
-
968
-
Supplementary Information about selection criteria
-
From 975 enrolled patients:
Patients provided DNA samples: 906 samples
Patients provided Cotinine samples: 930 samples
Patients provided nasopharyngeal samples: 968 samples
Patients provided sputum samples: 11 samples
Children with acute asthma
|
Index ED visit (Baseline): demographics, treatment given, lung function assessment, determinants of response, PRAM scores, medications (current asthma, non-asthma and prescribed medications at the time of disposition), family history and environment, child’s asthma triggers, environmental exposures, disposition (admission/discharge), collection of biological samples, evaluation of airway inflammation.
-
Start Date
-
2011-02
-
End Date
-
2013-12
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Administrative databases
-
Data sources - Biosamples
-
-
Saliva
-
Other : Exhaled nitric oxide measurement; nasopharyngeal sample for virus; sputum sample for inflammatory cells.
-
Data sources - Administrative databases
-
-
Health databases
-
Environmental databases
-
Files
-
Index ED visit
|
|
FAMILY
|
The siblings population is composed of the older full siblings of the children to be born into the study.
-
Maximum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Hamilton and Burlington
-
Ethnic Origin
-
-
Health Status
-
-
Sources of recruitment
-
-
Specific Population
-
-
Other specific population : Older full siblings of the children included in the study.
-
Number of Participants
-
264
-
Number of Participants with Biological Samples
-
264
FAMILY - Siblings
|
Data collection occurred at study visits through questionnaires, physical measurements, and laboratory analysis of biological samples. Information about demographics, family health history, ethnicity, lifestyle practices (nutrition and associated behaviours, physical activity and associated behaviours, parental smoking history), socioeconomic status (education, income, postal code) were collected by questionnaire. Height, weight, waist and hip circumferences, subscapular and tricep skinfolds, and blood pressure were measured. Body mass index was calculated. Blood was also collected if the sibling is older than 5 years old, noted as fasting or non-fasting, and tested for glucose, insulin apolipoprotein A1, total cholesterol, HDL cholesterol and triglycerides.
-
Start Date
-
2004
-
End Date
-
2009
-
Data sources
-
-
Questionnaires
-
Physical measures
-
Biosamples
-
Data sources - Biosamples
-
-
Files
-
FAMILY - Siblings - 21-39 weeks of pregnancy
|